07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Phospholipase A2 group V (PLA2G5); PLA2G2E Mouse studies suggest stabilizing PLA2G5 or inhibiting PLA2G2E could...